The Effect of Severe Renal Impairment on the Pharmacokinetics Following Single-Dose Inhaled Administration of TD 4208
Phase of Trial: Phase I/II
Latest Information Update: 28 Feb 2018
At a glance
- Drugs Revefenacin (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Pharmacokinetics
- Sponsors Theravance Biopharma
- 09 Jun 2016 Status changed from recruiting to completed.
- 26 Jan 2016 Status changed from not yet recruiting to recruiting, according to ClinicalTrials.gov record.
- 19 Oct 2015 New trial record